In patients with immunoglobulin A nephropathy (IgAN), higher levels of proteinuria and lower baseline estimated glomerular filtration rate (eGFR) are strongly associated with adverse kidney outcomes — ...

Everest Medicines presents positive results in preliminary analysis of phase 1b/2a trial of novel BTK inhibitor EVER001 at ERA 2025 Congress: Shanghai, China Tuesday, June 10, 202 ...

Interestingly, proteinuria and glomerulosclerosis did not develop when weight gain and glomerular enlargement were prevented by dietary calorie restriction. The initial histological manifestation ...

Atacicept, an investigational BAFF (B-cell activating factor)/APRIL (a proliferation-inducing ligand) dual inhibitor, significantly reduced proteinuria in patients with immunoglobulin A nephropathy ...

Empaveli reduced proteinuria by 68% versus placebo in glomerulopathy and glomerulonephritis, an effect that was sustained ...

Sobi and Apellis Pharmaceuticals have reported new results from the open-label period of the randomised Phase III VALIANT ...

SHANGHAI, China I June 9, 2025 I Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical ...

A novel immunoglobulin A nephropathy (IgAN) drug cut proteinuria in half, according to interim findings from the ongoing ...

Significant reductions in proteinuria, estimated glomerular filtration rate stability of the C3/C3b inhibitor were also ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent ...

In the Phase III VISIONARY study, sibeprenlimab, an investigational monoclonal antibody, showed a 51.2% reduction in ...